Theratest EL-BETA2GPI (Igm-Igg-Iga), Theratest EL--BETA2GPI SCR
FDA 510(k) K092757 · Thera-Test Laboratories, Inc.
510(k) numberK092757
Submission
- Device name
- Theratest EL-BETA2GPI (Igm-Igg-Iga), Theratest EL--BETA2GPI SCR
- Applicant
- Thera-Test Laboratories, Inc.
Lombard, IL, US - Received
- September 9, 2009
- Decision date
- October 9, 2009
- Decision
- Substantially Equivalent (SESE)
- Type
- Special 510(k)
- Summary
- 510(k) statement available from FDA
Device classification
- Product code
- MSV – System,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi)
- Device class
- Class II (moderate risk)
- Regulation
- 21 CFR 866.5660
- Specialty
- Immunology
Other 510(k)s with product code MSV
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K243979 | Aptiva APS IgA ReagentMSV · Traditional | Inova Diagnostics, Inc. | 02/06/2026SE |
| K181329 | EliA B2-Glycoprotein I IgA Immunoassay, EliA Cardiolipin IgA ImmunoassayMSV · Traditional | Phadia AB | 06/25/2018SE |
| K162788 | ImmuLisa Enhanced B2GP1 IgA Antibody ELISA, ImmuLisa Enhanced B2GP1 IgG Antibody ELISA…MSV · Traditional | Immco Diagnostics, Inc. | 06/19/2017SE |
| K152875 | QUANTA Flash B2GP1-Domain1, QUANTA Flash B2GP1-Domain1 Controls, HemosIL AcuStar…MSV · Traditional | Inova Diagnostics, Inc. | 12/21/2015SE |
| K141274 | Quanta Flash ¿2GP1-DOMAIN1; Controls, Hemosil Acustar ANTI-¿2GPI DOMAIN1; Controls.MSV · Traditional | Inova Diagnostics, Inc. | 02/13/2015SE |
| K112414 | Elia B2-GLYCOPROTEIN I Iga ImmunoassayMSV · Traditional | Phadia US, Inc. | 06/22/2012SE |
| K091556 | Hemosil Acustar ANTI-B2 Glycoprotein-I; Igg, Igm, Igg Controls, Igm ControlsMSV · Traditional | Instrumentation Laboratory CO | 05/21/2010SE |
| K072032 | Igg Anti-Atherox Test KitMSV · Traditional | Corgenix, Inc. | 04/04/2008SE |
| K062217 | Aeskulska BETA2-GLYCO-AMSV · Traditional | Aesku, Inc. | 12/13/2006SE |
| K040452 | Varelisa B2 Glycoprotein I Antibodies Screen, Models 19048 and 19096MSV · Traditional | Pharmacia Deutschland GmbH | 05/11/2004SE |
Questions and answers
When was Theratest EL-BETA2GPI (Igm-Igg-Iga), Theratest EL--BETA2GPI SCR cleared by the FDA?
Theratest EL-BETA2GPI (Igm-Igg-Iga), Theratest EL--BETA2GPI SCR (K092757) received a 510(k) decision of Substantially Equivalent on October 9, 2009, 30 days after the submission was received.
What is the product code of K092757?
The FDA product code is MSV – System,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi), a Class II (moderate risk) device regulated under 21 CFR 866.5660.